Genentech announced positive topline results from two identically designed global Phase III studies, TENAYA and LUCERNE, evaluating its investigational bispecific […]
Ocuphire Pharmaceuticals announced that results from its ORION-1 Phase 2 clinical trial evaluating the safety and efficacy of Nyxol in glaucoma […]
Bausch + Lomb announced that the results from the Phase 2 SEECASE clinical study, evaluating NOV03 (perfluorohexyloctane) ophthalmic solution in […]
In a recent special piece for Ophthalmology Times Dr. Jason R. Chin with Andover Eye (Andover, MA) and Dr. Gary […]
Researchers are developing a powerful, new kind of patient registry by using optical coherence tomography, angiography, and ultra-widefield fundus photography. […]
Enthera Pharmaceuticals announced the completion of a €28 million Series A financing round co-led by seed investor Sofinnova Partners and […]
Kaiser Permanente investigators are looking into the underlying genetic factors behind near-sightedness or myopia. The team has closed in on […]
Applied Genetics Technologies Corp. announced positive interim six-month data from the dose-escalation cohorts of its ongoing Phase 1/2 clinical trials, […]
Horizon Therapeutics announced the U.S. FDA has approved Tepezza (teprotumumab-trbw) for the treatment of Thyroid Eye Disease (TED). Tepezza is […]
Oyster Point Pharma announced positive results from their phase 2 Mystic trial, which evaluated OC-01 nasal spray as compared to […]
